… in development for chronic obstructive pulmonary disease. This … None of the patients had a
history of asthma. The protocol … rate at efficacious and long-acting doses, which confirmed the …

… as asthma and chronic obstructive pulmonary disease (COPD). … classes of bronchodilator
and in identifying novel classes of … inhaled long-acting β 2 -adrenoceptor agonists (LABAs) and …

… COPD reported that triple therapy was the most common treatment regimen at admission.
Citation30 Variations in asthma … stratify our results by COPD and/or asthma diagnosis, but this …

… long-acting β 2 agonist (LABA) combined with a long-acting … for managing moderate to
severe COPD. Since 2017, the … with a history of asthma or asthma-COPD overlap or with a blood …

… treatments for COPD patients, including long-acting muscarinic antagonist (LAMA), long-acting
β2-… Patients with asthma, other respiratory disorders, such as bronchiectasis or unclear …

… Olodaterol (OLO) is a novel once-daily LABA bronchodilator that was effective in lung … dual
long-acting bronchodilators (UME/VIL, IND/GLY, and TIO/OLO) used on patients with COPD …

… The participants were asked to refrain from using short-acting β 2 -agonists for ≥6 h, long-acting
β 2 -agonists for 12 h and long-acting antimuscarinic agents for 24 h before performing …

… Long-acting muscarinic antagonists (LAMAs) have a recognised role in the … of chronic
obstructive pulmonary disease. In asthma, muscarinic antagonists (both short- and long-acting) …

… Short-acting bronchodilators are indicated as monotherapy in patients … long-acting
bronchodilators are recommended as initial maintenance therapy for patients with a history of …

… in patients with asthma with the use of long-acting 2 agonist … to include a long-acting
bronchodilator in conjunction with … in both asthma and COPD has led to the identification of novel …